https://www.live-feeds.com/feed/how-did-a-heart-drug-with-so-much-promise-fall-so-flatContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/how-did-a-heart-drug-with-so-much-promise-fall-so-flathttps://www.live-feeds.com/feed/how-did-a-heart-drug-with-so-much-promise-fall-so-flat#u69697Wed, 16 Sep 2026 02:26:51 +0000Pharmaceutical research into high-profile cardiovascular treatments is facing a slowdown following drug failures at Novo Nordisk and Novartis. These setbacks have dampened expectations for a multibillion-dollar therapeutic sector and are negatively impacting the Dow. Financial analysts and medical experts are now scrutinizing clinical outcomes as companies reevaluate the trajectory of these treatments. The lack of successful results has created significant uncertainty regarding the future of these promising therapies across both the medical and financial sectors.Why it mattersThe cardiovascula https://www.live-feeds.com/feed/how-did-a-heart-drug-with-so-much-promise-fall-so-flathttps://www.live-feeds.com/feed/how-did-a-heart-drug-with-so-much-promise-fall-so-flat#u67613Mon, 14 Sep 2026 07:45:41 +0000Recent drug failures from major pharmaceutical companies like Novartis and Novo Nordisk are stalling momentum in a multibillion-dollar therapeutic field. Observers warn that these setbacks will pop a hole in the balloon of high-profile cardiovascular drug research. Market analysts report that the struggles are weighing heavily on stock performance, specifically pulling down the Dow. As companies reevaluate clinical outcomes, the future trajectory of these promising treatments faces heightened scrutiny and uncertainty across the medical and financial sectors.Why it mattersPharmaceutical develop